Western pharma groups warn of supply disruptions over China anti-spy law
China’s anti-espionage laws have caused concern among western pharmaceutical groups over potential arrests or denial of access for foreign inspectors in China-based facilities and manufacturing partners, posing a risk to the supply of drug products such as generics and antibiotics.
Western pharmaceutical groups with manufacturing sites in China are voicing concerns around the enforcement of anti-espionage laws by the Chinese government, with fears of arrest for foreign factory inspectors and others denied entry to sites.
Many multinational companies across various sectors have increasingly brought attention to the issue of data sovereignty, with nations vying for control and ownership of data. China, as with the US and EU, also possesses strict data regulation and localisation laws – namely, the requirement of storing and processing of data within the country’s borders. Coupled with a call to decouple data from China’s information infrastructure, many pharma foreign pharma companies are either refusing to enter the nation over fears of espionage accusations, or are being denied entry to manufacturing facilities in China. Geopolitical tensions between China and western nations have compounded these fears.
Consequently, foreign regulators are struggling to enforce oversight over their Chinese manufacturing facilities and partners. EU and US pharma regulations require certification from government inspectors and audits in order to manufacture drug products in third-party countries. The potential for some Chinese manufacturing facilities to lose this certification without the proper inspection, the already strained pharma supply chain risks even more disruptions in the supply of generic pharmaceuticals. The onset of the COVID-19 pandemic demonstrated just how important China is in the supply and manufacture of generic APIs and pharmaceuticals, with record shortages of essential drugs to the US and EU just in the last 5 years. China is also one of the largest manufacturers of antibiotics for companies around the world. On top of this, incomplete inspections from certifications carried out online or prolonged delays during the pandemic has created a backlog of audits due to expire by the end of this year, stated Fatima Bicane, manager of pharmaceutical technology at the German Medicines Manufacturer’s Association (BAH).
“The big issue we have is that our member companies, in order to bring active ingredients and finished drug products from China to the EU, need certification from certain authorities,” Bicane commented. “But a large number of German inspectors are afraid to travel to China because of the new national security law.” Concerns over the ambiguity of China’s anti-espionage law have caused concern over who can be accused of espionage.
The US FDA claims that agency inspectors have been turned away from factories in China since 2021, with 150 incidences of US FDA inspections being refused. While no western pharmaceutical inspector has been detained, there has been one incident of the arrest of a Japanese executive from Astellas Pharma. A spokesperson from China’s Ministry of Foreign Affairs commented, “China is a country ruled by law. All Chinese law enforcement and judicial activities are carried out based on facts and the law. As long as one abides by Chinese laws and regulations, there is no need to worry.”
Source
Pharma groups warn of supply crunch over China spying law [Accessed April 22, 2024] https://www.ft.com/content/1d52d75f-5b54-4c27-bdd4-65409f64c64a
Related News
-
News More to celebrate at the CPHI Milan Pharma Awards 2024
The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona... -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance